These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18278183)

  • 1. Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis.
    Adomaityte J; Farooq M; Qayyum R
    Thromb Haemost; 2008 Feb; 99(2):338-42. PubMed ID: 18278183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Raloxifene in postmenopausal women].
    Trémollières F; Ribot C
    Gynecol Obstet Fertil; 2006 Feb; 34(2):147-53. PubMed ID: 16483822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety assessment of raloxifene over eight years in a clinical trial setting.
    Martino S; Disch D; Dowsett SA; Keech CA; Mershon JL
    Curr Med Res Opin; 2005 Sep; 21(9):1441-52. PubMed ID: 16197663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Which is the better choice, estrogen or SERMs in postmenopausal women?].
    Shintani M
    Clin Calcium; 2004 Oct; 14(10):105-10. PubMed ID: 15577140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raloxifene and risk for stroke based on the framingham stroke risk score.
    Barrett-Connor E; Cox DA; Song J; Mitlak B; Mosca L; Grady D
    Am J Med; 2009 Aug; 122(8):754-61. PubMed ID: 19540454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.
    Ensrud K; Genazzani AR; Geiger MJ; McNabb M; Dowsett SA; Cox DA; Barrett-Connor E
    Am J Cardiol; 2006 Feb; 97(4):520-7. PubMed ID: 16461049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
    Barrett-Connor E; Mosca L; Collins P; Geiger MJ; Grady D; Kornitzer M; McNabb MA; Wenger NK;
    N Engl J Med; 2006 Jul; 355(2):125-37. PubMed ID: 16837676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women.
    Neven P; Goldstein SR; Ciaccia AV; Zhou L; Silfen SL; Muram D
    Gynecol Oncol; 2002 May; 85(2):388-90. PubMed ID: 11972407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
    Abramson N; Costantino JP; Garber JE; Berliner N; Wickerham DL; Wolmark N
    J Natl Cancer Inst; 2006 Jul; 98(13):904-10. PubMed ID: 16818854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
    Lippman ME; Cummings SR; Disch DP; Mershon JL; Dowsett SA; Cauley JA; Martino S
    Clin Cancer Res; 2006 Sep; 12(17):5242-7. PubMed ID: 16951244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of raloxifene therapy on the anticoagulant system in postmenopausal women.
    Azevedo GD; Franco RF; Baggio MS; Maranhão TM; Ferriani RA; Silva de Sá MF
    Climacteric; 2003 Jun; 6(2):140-5. PubMed ID: 12841884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for using raloxifene to prevent both osteoporosis and breast cancer in postmenopausal women.
    Lee WL; Chao HT; Cheng MH; Wang PH
    Maturitas; 2008 Jun; 60(2):92-107. PubMed ID: 18534794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of SERMs on bone health. Raloxifene effects on breast cancer and cardiovascular events].
    Inoue D
    Clin Calcium; 2010 Mar; 20(3):331-8. PubMed ID: 20190362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [SERM & bone metabolism: protective effects of SERM against fracture risk and its long-term beneficial effects].
    Inaba M
    Clin Calcium; 2004 Oct; 14(10):27-31. PubMed ID: 15577128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen treatment and risk of deep venous thrombosis and pulmonary embolism: a Danish population-based cohort study.
    Hernandez RK; Sørensen HT; Pedersen L; Jacobsen J; Lash TL
    Cancer; 2009 Oct; 115(19):4442-9. PubMed ID: 19569248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on Mobley and Others: importance of assumptions about VTE mortality in modeling the cost-effectiveness of osteoporosis therapies.
    Meadows ES; Stock J; Johnston JA
    Med Decis Making; 2006; 26(6):633-5; author reply 636-7. PubMed ID: 17099202
    [No Abstract]   [Full Text] [Related]  

  • 19. [Selective estrogen receptor modulators (SERM's) in postmenopausal women].
    Kleiverda G
    Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2446-7. PubMed ID: 10608980
    [No Abstract]   [Full Text] [Related]  

  • 20. Venous thrombosis and conjugated equine estrogen in women without a uterus.
    Curb JD; Prentice RL; Bray PF; Langer RD; Van Horn L; Barnabei VM; Bloch MJ; Cyr MG; Gass M; Lepine L; Rodabough RJ; Sidney S; Uwaifo GI; Rosendaal FR
    Arch Intern Med; 2006 Apr; 166(7):772-80. PubMed ID: 16606815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.